Comparative Risk of Injury with Concurrent Use of Opioids and Skeletal Muscle Relaxants.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
received:
11
10
2023
accepted:
02
03
2024
medline:
14
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
aheadofprint
Résumé
Concurrent use of skeletal muscle relaxants (SMRs) and opioids has been linked to an increased risk of injury. However, it remains unclear whether the injury risks differ by specific SMR when combined with opioids. We conducted nine retrospective cohort studies within a US Medicaid population. Each cohort consisted exclusively of person-time exposed to both an SMR and one of the three most dispensed opioids-hydrocodone, oxycodone, and tramadol. Opioid users were further divided into three cohorts based on the initiation order of SMRs and opioids-synchronically triggered, opioid-triggered, and SMR-triggered. Within each cohort, we used Cox proportional hazard models to compare the injury rates for different SMRs compared to methocarbamol, adjusting for covariates. We identified 349,543, 139,458, and 218,967 concurrent users of SMRs with hydrocodone, oxycodone, and tramadol, respectively. In the oxycodone-SMR-triggered cohort, the adjusted hazard ratios (HRs) were 1.86 (95% CI, 1.23-2.82) for carisoprodol and 1.73 (1.09-2.73) for tizanidine. In the tramadol-synchronically triggered cohort, the adjusted HRs were 0.69 (0.49-0.97) for metaxalone and 0.62 (0.42-0.90) for tizanidine. In the tramadol-SMR-triggered cohort, the adjusted HRs were 1.51 (1.01-2.26) for baclofen and 1.48 (1.03-2.11) for cyclobenzaprine. All other HRs were statistically nonsignificant. In conclusion, the relative injury rate associated with different SMRs used concurrently with the three most dispensed opioids appears to vary depending on the specific opioid and the order of combination initiation. If confirmed by future studies, clinicians should consider the varying injury rates when prescribing SMRs to individuals using hydrocodone, oxycodone, and tramadol.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Soprano, S.E., Hennessy, S., Bilker, W.B. & Leonard, C.E. Assessment of physician prescribing of muscle relaxants in the United States, 2005-2016. JAMA Netw. Open 3, e207664 (2020).
Li, Y., Delcher, C., Reisfield, G.M., Wei, Y.J., Brown, J.D. & Winterstein, A.G. Utilization patterns of skeletal muscle relaxants among commercially insured adults in the United States from 2006 to 2018. Pain Med. 22, 2153-2161 (2021).
Musich, S., Wang, S.S., Slindee, L., Kraemer, S. & Yeh, C.S. Characteristics associated with transition from opioid initiation to chronic opioid use among opioid-naïve older adults. Geriatr. Nurs. 40, 190-196 (2019).
Larochelle, M.R., Zhang, F., Ross-Degnan, D. & Wharam, J.F. Trends in opioid prescribing and co-prescribing of sedative hypnotics for acute and chronic musculoskeletal pain: 2001-2010. Pharmacoepidemiol. Drug Saf. 24, 885-892 (2015).
FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. FDA <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or> (2019).
Li, Y. et al. Risk of opioid overdose associated with concomitant use of opioids and skeletal muscle relaxants: a population-based cohort study. Clin. Pharmacol. Ther. 108, 81-89 (2020).
Khan, N.F., Bykov, K., Barnett, M.L., Glynn, R.J., Vine, S.M. & Gagne, J.J. Comparative risk of opioid overdose with concomitant use of prescription opioids and skeletal muscle relaxants. Neurology 99, e1432-e1442 (2022).
Leonard, C.E. et al. Screening to identify signals of opioid drug interactions leading to unintentional traumatic injury. Biomed. Pharmacother. 130, 110531 (2020).
Haagsma, J.A. et al. The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the global burden of disease study 2013. Inj. Prev. 22, 3-18 (2016).
Hernán, M.A., Wang, W. & Leaf, D.E. Target trial emulation: a framework for causal inference from observational data. JAMA 328, 2446-2447 (2022).
Hennessy, S. et al. Methods for studying the health effects of drug-drug interactions. In Pharmacoepidemiology (eds. Strom, B. L., Kimmel, S. E. & Hennessy, S.) 1030-1045 (Wiley-Blackwell, John Wiley & Sons, Ltd, Hoboken, NJ, 2022).
Hennessy, S. et al. Pharmacoepidemiologic methods for studying the health effects of drug-drug interactions (DDIs). Clin. Pharmacol. Ther. 99, 92-100 (2016).
See, S. & Ginzburg, R. Choosing a skeletal muscle relaxant. Am. Fam. Physician 78, 365-370 (2008).
Witenko, C. et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low Back pain. P T 39, 427-435 (2014).
Berger, A.S. Non-Opioid Analgesics & Adjunctive Medications <https://med.stanford.edu/content/dam/sm/pedsanesthesia/documents/adjunctive-medications.pdf>.
National Trauma Data Bank. ACS <https://www.facs.org/quality-programs/trauma/quality/national-trauma-data-bank/>.
Injury Data and Resources - ICD Injury Matrices <https://www.cdc.gov/nchs/injury/injury_matrices.htm> (2021).
Wright, N.C., Daigle, S.G., Melton, M.E., Delzell, E.S., Balasubramanian, A. & Curtis, J.R. The design and validation of a new algorithm to identify incident fractures in administrative claims data. J. Bone Miner. Res. 34, 1798-1807 (2019).
Bazarian, J.J., Veazie, P., Mookerjee, S. & Lerner, E.B. Accuracy of mild traumatic brain injury case ascertainment using ICD-9 codes. Acad. Emerg. Med. 13, 31-38 (2006).
Hagen, E.M., Rekand, T., Gilhus, N.E. & Gronning, M. Diagnostic coding accuracy for traumatic spinal cord injuries. Spinal Cord 47, 367-371 (2009).
Kim, D.H., Schneeweiss, S., Glynn, R.J., Lipsitz, L.A., Rockwood, K. & Avorn, J. Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J. Gerontol. A Biol. Sci. Med. Sci. 73, 980-987 (2018).
Spence, M.M., Shin, P.J., Lee, E.A. & Gibbs, N.E. Risk of injury associated with skeletal muscle relaxant use in older adults. Ann. Pharmacother. 47, 993-998 (2013).
Yoshikawa, A. et al. Opioid use and the risk of falls, fall injuries and fractures among older adults: a systematic review and meta-analysis. J. Gerontol. A Biol. Sci. Med. Sci. 75, 1989-1995 (2020).
Li, F. Propensity score weighting for causal inference with multiple treatments. Ann. Appl. Stat. 13, 2389-2415 (2019).
LeMier, M., Cummings, P. & West, T.A. Accuracy of external cause of injury codes reported in Washington state hospital discharge records. Inj. Prev. 7, 334-338 (2001).
Bowman, S.M. & Aitken, M.E. Assessing external cause of injury coding accuracy for transport injury hospitalizations. Perspect. Health Inf. Manag. 8, 1c (2011).
Rothman, K.J. No adjustments are needed for multiple comparisons. Epidemiology 1, 43-46 (1990).
Chen, C., Winterstein, A.G., Lo-Ciganic, W.-H., Tighe, P.J. & Wei, Y.-J.J. Concurrent use of prescription gabapentinoids with opioids and risk for fall-related injury among older US Medicare beneficiaries with chronic noncancer pain: a population-based cohort study. PLoS Med. 19, e1003921 (2022).
Chou, R., Peterson, K. & Helfand, M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J. Pain Symptom Manag. 28, 140-175 (2004).
Beebe, F.A., Barkin, R.L. & Barkin, S. A clinical and pharmacologic review of skeletal muscle relaxants for musculoskeletal conditions. Am. J. Ther. 12, 151-171 (2005).
Frydrych, V. & Oderda, G. Skeletal Muscle Relaxants Drug Class Review: 12:20.04 Centrally Acting Skeletal Muscle Relaxants <https://medicaid.utah.gov/pharmacy/ptcommittee/files/Criteria%20Review%20Documents/2016/2016.02%20Skeletal%20Muscle%20Relaxant%20Class%20Review.pdf> (2016).
Beltrán-Villalobos, K.L., Ramírez-Marín, P.M., Cruz, C.A.Z. & Déciga-Campos, M. Coadministration of tramadol and tizanidine in an experimental acute pain model in rat. Drug Dev. Res. 75, 473-478 (2014).
Raffa, R.B. et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J. Pharmacol. Exp. Ther. 260, 275-285 (1992).
Turturro, M.A., Paris, P.M. & Larkin, G.L. Tramadol vs. hydrocodone-acetaminophen in acute musculoskeletal pain: a randomized, double-blind clinical trial. Ann. Emerg. Med. 32, 139-143 (1998).
Dayer, P., Collart, L. & Desmeules, J. The pharmacology of tramadol. Drugs 47, 3-7 (1994).
Terman, G. Is Tramadol an Opioid or a Nonopioid Analgesic? Yes! <https://wmc.wa.gov/sites/default/files/public/Newsletter/IsTramadolanOpioid.pdf> (2020).
Shimonovich, M., Pearce, A., Thomson, H., Keyes, K. & Katikireddi, S.V. Assessing causality in epidemiology: revisiting Bradford Hill to incorporate developments in causal thinking. Eur. J. Epidemiol. 36, 873-887 (2021).
Baskin-Sommers, A. & Sommers, I. The co-occurrence of substance use and high-risk behaviors. J. Adolesc. Health 38, 609-611 (2006).